Merck builds on leading viral and gene therapy service offering with capacity expansion
Larger Carlsbad, California facility will allow seamless scale-up customer support from clinical to commercial scales.
Merck has announced an expansion of its Carlsbad, California facility to meet growing demand for viral and gene therapy products.
Scheduled for completion in 2016, the Carlsbad campus will increase from 44,000 sq ft to 65,000 sq ft, with 16 modular viral bulk manufacturing cleanroom suites, two fill/finish suites and twice the warehouse capacity. The expansion will incorporate single-use equipment in a flexible, scalable format for clinical and commercial bulk drug production.
"We are building on our industry-leading offerings in the manufacturing and testing of innovative and complex products, underscoring our commitment to being a trusted, long-term partner of choice," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. The company's new capacity at Carlsbad positions Merck to seamlessly support customers from clinical to commercial scales, and is complemented by cell-banking services in Rockville, Maryland, viral and gene therapy manufacturing capacity in Glasgow, Scotland and global BioReliance biosafety testing offering.
The Carlsbad facility – Merck's flagship site for SAFC's viral and gene therapies offering — will remain fully operational throughout the expansion. The Carlsbad campus features segregated fill/finish capacity for gene therapy, viral vaccine and immunotherapy products. Merck's teams have decades of combined experience in the viral, gene therapy and biosafety testing sectors.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance